-
Media ReleaseNew data at ASH to reinforce breadth of Novartis hematology portfolio across multiple blood cancers and serious hematologic diseases
-
Media ReleaseNew Novartis analyses for investigational inclisiran demonstrate consistently effective and sustained LDL-C reduction at month 17, regardless of age and gender
-
Media ReleaseNovartis Cosentyx® shows early synovitis reduction in patients with psoriatic arthritis in first-of-its-kind study
-
Media ReleaseNovartis announces five-year data that reinforce the safety and efficacy profile of Aimovig® (erenumab-aooe) in adult patients with episodic migraine
-
Media ReleaseNovartis US Foundation commits $25M to improve health equity by reducing health disparities in the US
-
Media ReleaseNovartis presents data at ACTRIMS-ECTRIMS for Kesimpta® (ofatumumab) in newly diagnosed treatment-naïve adults with relapsing multiple sclerosis
-
Media ReleaseNovartis new analysis shows high consistency in lowering LDL-C in individual response with investigational inclisiran
-
Media ReleaseNovartis launches PsO in the Know podcast series hosted by music icon Cyndi Lauper
-
Media ReleaseFDA approves Novartis Kesimpta® (ofatumumab), the first and only self-administered, targeted B-cell therapy for patients with relapsing multiple sclerosis
-
Media ReleaseNovartis announces FDA filing acceptance of Xolair® (omalizumab) prefilled syringe for self-administration across all indications
-
Media ReleaseNovartis announces NEJM publication of Phase III ASCLEPIOS trials demonstrating superior efficacy of ofatumumab in patients with relapsing multiple sclerosis
-
Media ReleaseNovartis Cosentyx receives FDA approval for new indication to treat active non-radiographic axial spondyloarthritis